Published in AIDS Weekly, March 14th, 2011
"Among CDKs, CDK9 is a validated pathological target in HIV infection, inflammation and cardiac hypertrophy; however selective CDK9 inhibitors are still not available. We present a selective inhibitor family of CDK9 based on the 4-phenylamino-6-phenylpyrimidine nucleus. We...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2011-03-14)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.